Johnson & Johnson’s pharmaceutical sales have been above-market for the past seven years and the firm plans to maintain that trend, largely on the continued strength of its oncology and immunology portfolios. J&J execs explained during a pharmaceuticals business review how recent launches and line extensions will allow it to deliver that growth.
Oncology is becoming an increasingly important therapeutic area for J&J, and along with the more established immunology business, is one...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
